A randomized, placebo-controlled, double-blind, prospective trial to evaluate the effect of vildagliptin in new-onset diabetes mellitus after kidney transplantation

Abstract

BACKGROUND New-onset diabetes mellitus after transplantation (NODAT), a frequent and serious complication after transplantation, is associated with decreased graft and patient survival. Currently, it is diagnosed and treated primarily according to existing guidelines for type II diabetes. To date, only a few trials have studied antidiabetic drugs in… (More)
DOI: 10.1186/1745-6215-11-91

Topics

3 Figures and Tables

Cite this paper

@inproceedings{Haidinger2010ARP, title={A randomized, placebo-controlled, double-blind, prospective trial to evaluate the effect of vildagliptin in new-onset diabetes mellitus after kidney transplantation}, author={Michael Haidinger and Johannes M Werzowa and H. Voigt and Johannes Pleiner and Gunar Stemer and Manfred Hecking and Dominik D{\"o}ller and Walter Hermann H{\"o}rl and Thomas Weichhart and Marcus D. S{\"a}emann}, booktitle={Trials}, year={2010} }